• Equity PC Ratio   0.57
  • |
  • Index PC Ratio   1.14
  • |
  • Total PC Ratio   0.97
  • |
  • VIX PC Ratio   0.54
  • VIX 14.02
  • VXN 16.95
  • VXO 14.44
  • ISEE 85.00

TruCharts Trading Strategies and Stock Buy/Sell Reports
(Show Details)


Chart Settings
No saved settings found!

Chart Type:
From: / / To: / /
Show detail in :
 Chart Skins:      
Price Overlays:





Indicator Windows:





Company Profile

Inovio Pharmaceuticals, Inc. engages in the discovery, development, and delivery of DNA vaccines with a focus on cancers and infectious diseases. Its SynCon technology enables the design of DNA-based vaccines capable of providing cross-protection against evolving, unmatched strains of pathogens, such as influenza. The company?s proprietary electroporation DNA delivery technology uses controlled electrical pulses to enhance cellular DNA vaccine uptake. The company?s clinical programs include trials for human papillomavirus/cervical cancer (therapeutic), avian influenza (preventative), hepatitis C virus, and human immunodeficiency virus vaccines. It also advances preclinical research for seasonal/pandemic influenza vaccine. Inovio Pharmaceuticals? partners and collaborators include University of Pennsylvania, National Microbiology Laboratory of the Public Health Agency of Canada, NIAID, Merck, ChronTech, University of Southampton, and HIV Vaccines Trial Network. The company was formerly known as Inovio Biomedical Corporation and changed its name to Inovio Pharmaceuticals, Inc. on May 14, 2010. Inovio Pharmaceuticals was founded in 1983 and is headquartered in Blue Bell, Pennsylvania.

NO
     
INO (Inovio Pharmaceuticals Inc)
Last Trade 3.635 Date 2/21/2020
Change % -4.60 % Price Change -0.18
Open 3.76 52 Week High 5.95
High 3.79 52 Week Low 1.915
Low 3.57 Type stock
Volume 4935164 Average Volume 5771675
Prev Close 3.81 Stock Exchange NASDAQ
Bid 3.63 Ask 3.64
Bid Size 171 Ask Size 67
1st Yr Estimated EPS Growth -0.2712 2nd Yr Estimated EPS Growth -0.0349
2 Years Forward Earning Yield -0.2178 2 Years Forward PE Ratio
2 Years EV/Forward EBIT 2 Years EV/Forward EBITDA
Book Value per Share 0.3324 Book Value Yield 0.0872
Buy Back Yield CAPE Ratio
Cash Return -0.2662 Cash Flow per Share -1.038
Cash Flow Yield -0.2724 Dividend Rate
Dividend Yield 5 Year Dividend Yield
Earning Yield -0.3097 EV/EBIT
EV/EBITDA EV / Free Cash Flow
EV / Forward EBIT EV / Forward EBITDA
EV / Forward Revenue 101.4277 EV / Pre Tax Income
EV / Revenue 60.84 EV / Total Asset 2.5435
Expected Dividend Growth Rate Free Cash Flow per Share -1.0505
Free Caash Flow Ratio Free Cash Flow Yield -0.2757
Forward Calculation Style Forward Dividend Yield
Forward Earning Yield -0.2257 Forward PE Ratio
Forward Return on Asset Forward Return on Equity
Normalized PE Ratio Payout Ratio 0.0
PB Ratio 11.461698 PB Ratio 10 Year Growth 0.176477
PB Ratio 3 Year Growth 4.434228 Cash Ratio 3 Year Average 408.682
Price to Cash Flow Ratio PEG Payback
PEG Ratio PE Ratio
PE Ratio 10 Year Average PE Ratio 10 Year Growth
PE Ratio 10 Year High PE Ratio 10 Year Low
PE Ratio 1 Year Avg PE Ratio 1 Year High
PE Ratio 1 Year Low PE Ratio 3 Year Avg
PE Ratio 5 Year Avg PE Ratio 5 Year High
PE Ratio 5 Year Low Free Cash Flow Ratio 10 Year Growth
Free Cash Flow Ratio 3 Year Avg Price Change 1 Month 0.84106
Price to Cash Ratio 4.117161 Price / EBITDA
Price to Sales Ratio 58.746575 Price to Sales Ratio 10 Year Growth 0.183512
Price to Sales Ratio 3 Year Avg 15.861798 Price to Sales Ratio 5 Year Avg
Sale per Share 0.0649 Sales Yield 0.017
Sustainable Growth Rate -1.6701 Tangible Book Value per Share 0.1896
Tangible Book Value per Share 3 year Avg 0.9004 Tangible Book Value per Share 5 year Avg 1.3823
Total Asset per Share 1.495 Total Yield
Working Capital per Share 0.782 Working Capital per Share 3 Year Avg 0.9328
Working Capital per Share 5 Year Avg 1.2858 Beta 2.706427